NIH Reporter #5F30CA278322-03

Research grant for anti-complement immunotherapy strategies for pancreatic cancer

This opportunity involves a research grant awarded by the National Cancer Institute (NCI), part of the NIH, to Albert Einstein College of Medicine for advancing anti-complement immunotherapy strategies targeting pancreatic cancer. - Government Buyer: - National Cancer Institute (NCI), NIH - Project conducted at Albert Einstein College of Medicine, Bronx, NY - Vendors and OEMs: - Primary vendor: Albert Einstein College of Medicine - No specific OEMs mentioned - Products and Services Requested: - Research supplies for immunotherapy studies - Animal care services for laboratory mice - Technical Focus: - Use of genetically modified mouse models to study complement activation in the tumor microenvironment - Evaluation of complement signaling inhibitors as potential therapeutics, alone and with radiotherapy - Investigation of immune cell and fibroblast responses in pancreatic ductal adenocarcinoma (PDAC) - Unique Requirements: - Advanced mouse models for cancer research - Application of various radiation modalities - Translational focus on complement-blocking therapeutics

Description

This project aims to develop novel immunotherapeutic strategies for pancreatic ductal adenocarcinoma (PDAC) by studying complement activation in the tumor microenvironment and its role in promoting oncogenesis. Using genetically modified mouse models, the research will explore how complement signaling affects immune cells and cancer-associated fibroblasts. The study will also evaluate translational therapeutics that block complement signaling alone and in combination with radiotherapy to improve treatment outcomes for PDAC. The project is funded by the National Cancer Institute and conducted by Albert Einstein College of Medicine.

View original listing